Komipharm International Co., Ltd.

KOSDAQ:A041960 Stock Report

Market Cap: ₩263.6b

Komipharm International Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Seong-Cheol Moon

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership0.6%
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

Impressive Earnings May Not Tell The Whole Story For Komipharm International (KOSDAQ:041960)

Nov 08
Impressive Earnings May Not Tell The Whole Story For Komipharm International (KOSDAQ:041960)

Is Komipharm International (KOSDAQ:041960) A Risky Investment?

Mar 27
Is Komipharm International (KOSDAQ:041960) A Risky Investment?

A Look At Komipharm International's (KOSDAQ:041960) Share Price Returns

Feb 26
A Look At Komipharm International's (KOSDAQ:041960) Share Price Returns

Is Komipharm International Co., Ltd.'s (KOSDAQ:041960) Shareholder Ownership Skewed Towards Insiders?

Jan 22
Is Komipharm International Co., Ltd.'s (KOSDAQ:041960) Shareholder Ownership Skewed Towards Insiders?

Komipharm International (KOSDAQ:041960) Is Carrying A Fair Bit Of Debt

Dec 18
Komipharm International (KOSDAQ:041960) Is Carrying A Fair Bit Of Debt

CEO

Seong-Cheol Moon (65 yo)

no data

Tenure

Mr. Seong-Cheol Moon serves as Managing Director of DONGBANG AGRO Corporation and served as its Assistant Managing Director. Mr. Moon serves as Chief Executive Officer and President at Komipharm Internatio...

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:56
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Komipharm International Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution